Hookipa Pharma and Roche Sign License Agreement to Develop Immunotherapy for KRAS-mutated Cancers
October 21, 2022
Trending News ☀️
Hookipa Pharma Stock Fair Value – Hookipa Pharma ($NASDAQ:HOOK) is a biotech company that focuses on developing immunotherapies. The company has recently signed a license agreement with Roche to develop HB-700, an immunotherapy for KRAS-mutated cancers. This is a significant development, as KRAS-mutated cancers are difficult to treat and have a high mortality rate.
Under the agreement, Roche will receive $25M upfront. The biotech company will have the option for an another product candidate, in which case Roche will get an additional $15M at option exercise.
Stock Price
The agreement gives Hookipa access to Roche’s resources and expertise, and could potentially lead to the development of an effective treatment for a type of cancer that is notoriously difficult to treat. The terms of the agreement are undisclosed, but it is likely that Hookipa will receive significant upfront and milestone payments, as well as royalties on any products that are commercialized. This could provide a major boost to Hookipa’s business, and could make it a major player in the cancer immunotherapy space.
VI Analysis – Hookipa Pharma Stock Fair Value
Hookipa Pharma is a clinical stage biopharmaceutical company developing a new class of immunotherapies against a range of infectious diseases and cancers. The company’s technology platform is based on its proprietary know-how in the field of virology and immunology. Hookipa’s technology platform is based on its proprietary know-how in the field of virology and immunology. Hookipa Pharma‘s fundamentals reflect its long term potential.
The intrinsic value of Hookipa Pharma‘s shares is around $5.3, calculated by VI Line. Now Hookipa Pharma‘s stock is traded at $1.3, undervalued by 75%.
VI Peers
The company’s pipeline includes two clinical-stage product candidates, HB-201 and HB-202, which are being evaluated in Phase I and Phase II clinical trials, respectively. HOOKIPA Pharma Inc’s main competitors are Applied Genetic Technologies Corp, Heat Biologics Inc, and TC BioPharm (Holdings) PLC.
– Applied Genetic Technologies Corp ($NASDAQ:AGTC)
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company that develops transformative gene therapies for patients suffering from severe genetic diseases or disorders. Its product candidates are in various stages of development for the treatment of achromatopsia, X-linked retinitis pigmentosa, albinism, and blue cone monochromacy.
– Heat Biologics Inc ($NYSEAM:HTBX)
Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics to treat serious and life-threatening medical conditions. The company’s market cap as of 2022 is 9.11M and its ROE is 71.6%. Incyte’s main therapeutic areas of focus are oncology and hematology. The company’s most notable products include Jakafi (ruxolitinib), a treatment for myelofibrosis and polycythemia vera; and Iclusig (ponatinib), a treatment for chronic myeloid leukemia.
Summary
Hookipa Pharma is a clinical-stage biopharmaceutical company that focuses on developing immunotherapies for the treatment of cancer and infectious diseases. Hookipa Pharma has partnered with Roche to develop an immunotherapy for KRAS-mutated cancers. Hookipa Pharma‘s stock price moved up the same day that the company announced a licensing agreement with Roche. This could be due to investors betting on the success of the immunotherapy being developed by the two companies.
